Fluticasone propionate intranasal - OptiNose

Drug Profile

Fluticasone propionate intranasal - OptiNose

Alternative Names: FLU-EDS; OPN-375; Opt-FP; OPTINOSE; OptiNose fluticasone propionate; XHANCE

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OptiNose AS
  • Developer OptiNose
  • Class Analgesics; Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Nasal polyps
  • Phase III Sinusitis
  • No development reported Asthma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Asthma in United Kingdom (Intranasal, Spray)
  • 18 Sep 2017 Registered for Nasal polyps in USA (Intranasal)
  • 03 Mar 2017 Pharmacokinetic data from phase I trials in healthy volunteers presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI - 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top